The US bank JPMorgan has left its rating for Bayer at Neutral with a target price of 34 euros ahead of the company s figures for the first quarter. After expectations have recently been put on a new.
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it s easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class.